Oxazinanes
Apexbio Technology LLC Rilmenidine (hemifumarate) 207572-68-7 5mg
Rilmenidine (hemifumarate CAS 207572-68-7) is an antihypertensive small molecule that primarily acts as an agonist at imidazoline I1 receptors within the rostral ventrolateral medulla thereby inhibiting the tonic activity of sympathoexcitatory neurons and reducing arterial pressure In vitro assays show that rilmenidine displays approximately 30-fold selectivity for imidazoline versus 2-adrenergic binding sites and a Ki of 7 1 nM for I1 receptors with significantly lower affinity for I2 sites (Ki 5 2 M) In vivo studies indicate efficacy in lowering blood pressure and ameliorating features of metabolic syndrome in rodent models as well as inducing autophagy and attenuating neurodegenerative pathology in a mouse model of Huntington s disease supporting its utility in cardiovascular and neurodegenerative research
Apexbio Technology LLC Rilmenidine (hemifumarate) 207572-68-7 10mg
Rilmenidine (hemifumarate CAS 207572-68-7) is an antihypertensive small molecule that primarily acts as an agonist at imidazoline I1 receptors within the rostral ventrolateral medulla thereby inhibiting the tonic activity of sympathoexcitatory neurons and reducing arterial pressure In vitro assays show that rilmenidine displays approximately 30-fold selectivity for imidazoline versus 2-adrenergic binding sites and a Ki of 7 1 nM for I1 receptors with significantly lower affinity for I2 sites (Ki 5 2 M) In vivo studies indicate efficacy in lowering blood pressure and ameliorating features of metabolic syndrome in rodent models as well as inducing autophagy and attenuating neurodegenerative pathology in a mouse model of Huntington s disease supporting its utility in cardiovascular and neurodegenerative research
Apexbio Technology LLC Rilmenidine (hemifumarate) 207572-68-7 50mg
Rilmenidine (hemifumarate CAS 207572-68-7) is an antihypertensive small molecule that primarily acts as an agonist at imidazoline I1 receptors within the rostral ventrolateral medulla thereby inhibiting the tonic activity of sympathoexcitatory neurons and reducing arterial pressure In vitro assays show that rilmenidine displays approximately 30-fold selectivity for imidazoline versus 2-adrenergic binding sites and a Ki of 7 1 nM for I1 receptors with significantly lower affinity for I2 sites (Ki 5 2 M) In vivo studies indicate efficacy in lowering blood pressure and ameliorating features of metabolic syndrome in rodent models as well as inducing autophagy and attenuating neurodegenerative pathology in a mouse model of Huntington s disease supporting its utility in cardiovascular and neurodegenerative research